MAPK9 and hepatocellular carcinoma: Pending safety results, it would be of great interest to evaluate CC-90001 in the context of hepatocellular carcinoma (HCC) and lung cancer [43–45], where JNK1, but not JNK2, has been implicated in tumor progression.